BOSTON -- A drug combination cured only a small fraction of patients with chronic hepatitis B (HBV), a researcher said here.
After
48 weeks of treatment with tenofovir (Viread) and pegylated interferon,
fewer than one patient in 10 lost the HBV surface antigen (HBsAg), the
gold standard for cure of the virus, according to Joerg Petersen, MD,
PhD, of the University of Hamburg in Germany.
But that was significantly better than either drug alone or a shorter combination of the two, Petersen reported at the American Association for the Study of Liver Diseases annual meeting.
Read more...Labels: AASLD 2014, tenofovir + pegylated interferon, Viread